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Abstract 
 
Background: When selecting predictive tools, for implementation in their clinical 
practice or for recommendation in clinical guidelines, clinicians are challenged with an 
overwhelming and ever-growing number of tools. Many of these have never been 
implemented or evaluated for comparative effectiveness. To overcome this challenge, 
the authors developed an evidence-based framework for grading and assessment of 
predictive tools (GRASP), based on the critical appraisal of their published evidence. The 
objective of this study is to validate, update GRASP, and evaluate its reliability.  
 
Methods: The study is composed of two parts. The first includes validating and 
updating the GRASP framework and the second includes evaluating the framework 
reliability. For the first part, an online survey was developed to collect the responses of 
a wide international group of experts; identified as healthcare researchers who have 
published studies on developing, implementing or evaluating predictive tools and 
clinical decision support systems. For the second part, the interrater reliability of the 
framework, to assign grades to eight predictive tools by two independent users, will be 
evaluated.  
 
Results: Out of 882 invited experts, 81 valid responses were received. On a five-
points Likert scale, experts overall strongly agreed to GRASP evaluation criteria of 
predictive tools (4.35/5). Experts strongly agreed to six criteria; predictive performance 
(4.87/5) and predictive performance levels (4.44/5), usability (4.68/5) and potential 
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effect (4.61/5), post-implementation impact (4.78/5) and evidence direction (4.26/5). 
Experts somewhat agreed to one criterion; post-implementation impact levels (4.16/5). 
Experts were neutral about one criterion; usability is higher than potential effect 
(2.97/5). Two thirds of the experts provided recommendations to six open-ended 
questions regarding adding, removing or changing evaluation criteria. Over half of the 
experts suggested that the potential effect, as an evaluation criterion, should be higher 
than the usability. Experts highlighted the importance of reporting the quality of studies 
and the strength of evidence supporting the grades assigned to predictive tools. The 
GRASP concept and its detailed report were updated based on experts’ feedback. 
Following validation, the interrater reliability of the GRASP framework, to produce 
accurate and consistent results by two independent users, was tested and the 
framework found to be reliable. Answering open-ended questions, the two independent 
users reported the GRASP framework was logical, useful, and easy to use.  
 
Discussion and Conclusion: The GRASP framework grades predictive tools 
based on the critical appraisal of the published evidence across three dimensions: 1) 
Phase of evaluation; 2) Level of evidence; and 3) Direction of evidence. The final grade 
of a tool is based on the highest phase of evaluation, supported by the highest level of 
positive evidence, or mixed evidence that supports positive conclusion. GRASP is not 
meant to be prescriptive; it provides clinicians with a high-level, evidence-based, and 
comprehensive, yet simple and feasible, approach to evaluate and compare clinical 
predictive tools, considering their predictive performance before implementation, 
potential effect and usability during planning for implementation, and post-
implementation impact on healthcare and clinical outcomes. 
 
Keywords: Evidence-Based Medicine, Clinical Decision Support, Clinical Prediction, 
Grading and Assessment, Validation. 
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1. Background 
 
Clinical decision support (CDS) systems have been proved to enhance evidence-
based clinical practice and support healthcare cost-effectiveness [1-6]. According to the 
definition developed by Edward Shortliffe, there are three levels of CDS functions, these 
include; 1) managing health information through providing tools for search and 
retrieval, 2) focusing users’ attention through flagging abnormal values or possible 
drug-to-drug interactions, and 3) providing patient specific recommendations based on 
the clinical scenario, which usually follow rules and algorithms, cost-benefit analysis or 
clinical pathways [7, 8]. Clinical predictive tools, here referred to simply as predictive 
tools, belong to the third level of CDS and include various applications; ranging from 
the simplest manual clinical prediction rules to the most sophisticated machine learning 
algorithms [9, 10]. These research-based applications provide diagnostic, prognostic, or 
therapeutic decision support. They quantify the contributions of relevant patient 
characteristics to derive the likelihood of diseases, predict their courses and possible 
outcomes, or support the decision making on their management [11, 12]. 
 
When selecting predictive tools, for implementation in their clinical practice or 
for recommendation in clinical practice guidelines, clinicians involved in the decision 
making are challenged with an overwhelming and ever-growing number of tools. Many 
of these tools have never been implemented or assessed for comparative performance 
or impact [13-15]. Currently, clinicians rely on their previous experience, subjective 
evaluation or recent exposure to predictive tools in making selection decisions. 
Objective methods and evidence based approached are rarely used in such decisions 
[16, 17]. Some clinicians, especially those developing clinical guidelines, search the 
literature for best available published evidence. Commonly they look for research 
studies that describe the development, implementation or evaluation of predictive 
tools. More specifically, some clinicians look for systematic reviews on predictive tools, 
comparing their predictive performance or development methods. However, there are 
no available approaches to objectively summarise or interpret such evidence [18, 19]. 
 
1.1. The GRASP Framework 
 
To overcome this major challenge, the authors have developed a new evidence-
based framework for grading and assessment of predictive tools (The GRASP 
Framework) [20]. The aim of this framework is to provide clinicians with standardised 
objective information on predictive tools to support their search for and selection of 
effective tools for their tasks. Based on the critical appraisal of the published evidence 
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on predictive tools, the GRASP framework uses three dimensions to grade predictive 
tools: 1) Phase of Evaluation, 2) Level of Evidence and 3) Direction of Evidence. 
 
Phase of Evaluation: Assigns A, B, or C based on the highest phase of evaluation. 
If a tool’s predictive performance, as reported in the literature, has been tested for 
validity, it is assigned phase C. If a tool’s usability and/or potential effect have been 
tested, it is assigned phase B. Finally, if a tool has been implemented in clinical practice, 
and there is published evidence evaluating its impact, it is assigned phase A. 
  
Level of Evidence: A numerical score, within each phase, is assigned based on 
the level of evidence associated with each tool. A tool is assigned grade C1 if it has been 
tested for external validity multiple times; C2 if it has been tested for external validity 
only once; and C3 if it has been tested only for internal validity. C0 means that the tool 
did not show sufficient internal validity to be used in clinical practice. Similarly, B1 is 
assigned to a predictive tool that has been evaluated during implementation for its 
usability; while if it has been studied for its potential effect on clinical effectiveness, 
patient safety or healthcare efficiency, it is assigned B2. Finally, if a predictive tool had 
been implemented then evaluated after implementation for its impact, on clinical 
effectiveness, patient safety or healthcare efficiency, it is assigned score A1 if there is 
at least one experimental study of good quality evaluating its impact, A2 if there are 
observational studies evaluating its impact and A3 if the impact has been evaluated 
through subjective studies, such as expert panel reports. 
 
Direction of Evidence: For each phase and level of evidence, a direction of 
evidence is assigned based on the collective conclusions reported in the studies. The 
evidence is considered positive if all studies about a predictive tool reported positive 
conclusions and negative if all studies reported negative or equivocal conclusions. The 
evidence is considered mixed if some studies reported positive and some reported 
either negative or equivocal conclusions. To decide an overall direction of evidence, a 
protocol is used to sort the mixed evidence into supporting an overall positive 
conclusion or supporting an overall negative conclusion. The protocol is based on two 
main criteria; 1) The degree of matching between the evaluation study conditions and 
the original predictive tool specifications, and 2) The quality of the evaluation study. 
Studies evaluating predictive tools in closely matching conditions to the tool 
specifications and providing high quality evidence are considered first for their 
conclusions in deciding the overall direction of evidence. The mixed evidence protocol 
is detailed and illustrated in Figure 6 in the Appendix. 
 
   5 
The final grade assigned to a tool is based on the highest phase of evaluation, 
supported by the highest level of positive evidence, or mixed evidence that supports a 
positive conclusion. The GRASP framework concept is shown in Figure 1 and the GRASP 
framework detailed report is presented in Table 3 in the Appendix.  
 
The predictive tool has been tested for internal validity
Tested for external validity only once
Tested for external validity multiple times
Estimated potential effect on healthcare
Reported usability testing
Based on subjective studies
Observational studies
Experimental studies
Clinical 
Effectiveness, 
Patient Safety or
A1
Phase A: Post
Implementation
Impact
Phase B: During
Implementation
Phase C: Pre
Implementation 
Performance
A2
A3
B1
B2
Assigned 
Grades
C1
C2
C3
GRASP Framework – Grading and 
Assessment of Predictive Tools 
for Clinical Decision Support
Healthcare Efficiency
Direction of 
Evidence
Positive
Negative
Mixed supporting 
positive conclusion
Mixed supporting 
negative conclusion
Phase of Evaluation
Level of 
Evidence
Figure 1: The GRASP Framework Concept [20] 
 
1.2. Study Objectives  
 
Validating new clinical instruments, healthcare models and evaluation 
frameworks through the feedback of experts is a well-established approach, especially 
in the area of CDS [12, 21, 22]. Using a mixed approach of qualitative and quantitative 
methods in research proved to be useful in healthcare, because of the complexity of the 
studied topics [23]. Using open-ended questions in quantitative surveys adds significant 
value and depth to both the results and conclusions of studies conducted [24]. The aim 
of this study is to validate and update the GRASP framework and to evaluate its 
reliability. The primary objective is to validate and update the criteria used by the 
GRASP framework, for grading and assessment of predictive tools, through the feedback 
of a wide international group of healthcare experts in the areas of developing, 
implementing and evaluating clinical decision support systems and predictive tools. 
The secondary objective is to evaluate the GRASP framework reliability to ensure that 
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the outcomes produced by independent users, when grading predictive tools using the 
GRASP framework, are accurate, consistent and reliable. 
 
2. Methods 
 
2.1. The Study Design 
 
The study is composed of two parts. The first part includes validating and 
updating the GRASP framework and the second part includes evaluating the framework 
reliability. For the first part, a survey was designed to solicit the feedback of experts on 
the criteria used by the GRASP framework for grading and assessment of predictive 
tools. The main outcome of this part of the study is to measure the validity and update 
the design and content of the GRASP framework. The analysis includes evaluating the 
degree of agreement of experts on how essential the different criteria used to grade 
predictive tools are, including the three dimensions; phases of evaluation (before, 
during and after implementation), levels of evidence and directions of evidence within 
each phase. In addition, experts’ feedback on adding, removing or updating any of the 
criteria, used to grade predictive tools, and their further suggestions and 
recommendations will also be analysed and considered. 
 
Based on similar studies; validating and updating systems through surveying 
expert users, it was estimated that the required sample size for this study is around 
fifty experts [25-28]. Experts were identified as researchers who have published at least 
one paper on developing, implementing or evaluating predictive tools and clinical 
decision support systems. To search for such publications, the concepts of Clinical 
Decision Support, Clinical Prediction, Developing, Validating, Implementing, Evaluating, 
Comparing, Reviewing, Tools, Rules, Models, Algorithms, Systems, and Pathways were 
used. The search engines used were MEDLINE, EMBASE, CINAHL and Google Scholar. For 
the purpose of emails currency, the search was restricted to the last three years. 
 
The study has been approved by the Human Research Ethics Committee, Faculty 
of Medicine and Health Sciences, Macquarie University, Sydney, Australia, on the 4
th
 of 
October 2018. The authors expected the distribution of the survey to take two weeks, 
and the collection of the feedback to take another four weeks. The authors expected the 
response rate to be around 10%. Before the deployment of the survey a pilot testing was 
conducted through asking ten experts to take the survey. The feedback of the pilot 
testing was used to improve the survey design and content; some questions were 
rephrased, some were rearranged, and some were supported by definitions and 
clarifications. Experts who participated in the pilot testing were excluded from the 
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participation in the final survey. An invitation email, introducing the study objectives, 
the survey completion time, which was estimated at 20 minutes, and a participation 
consent was submitted to the identified experts with the link to the online survey. A 
reminder email, in two weeks, was sent to the experts who have not responded or 
completed the survey. 
 
2.2. The Study Survey 
 
The online survey was developed using Qualtrics experience management 
platform [29]. The online survey, as illustrated through the screenshots in the 
Appendix, included eight five-points Likert scale closed-ended agreement questions and 
six open-ended suggestions and recommendations questions distributed over seven 
sections. The introduction informed the participants about the aim of developing the 
GRASP framework, its design, and the task they are requested to complete. In addition 
to informing them that they can request feedback and acknowledgement as well as 
providing them with contacts to ask for further information or to make complaints. The 
second section asked experts about their level of agreement with the evaluation of the 
published evidence on the tools’ predictive performance before implementation, such 
as internal and external validation. The third section asked experts about their level of 
agreement with the evaluation of the published evidence on the tools’ usability and/or 
potential effect on healthcare during implementation. The fourth section asked experts 
about their level of agreement with the evaluation of the published evidence on the 
tools’ post-implementation impact on clinical effectiveness, patient safety or healthcare 
efficiency. The fifth section asked experts about their level of agreement with the 
evaluation of the direction of the published evidence on the tools, being positive, 
negative or mixed. Experts were also requested to provide their free-text feedback on 
adding, removing or changing any of the criteria used for the assessment of phases of 
evaluation, levels of evidence, or directions of evidence. The sixth section asked experts 
to provide their free-text feedback on the best methods suggested to define and capture 
successful tools' predictive performance, when different clinical prediction tasks have 
different predictive performance requirements. Experts were also asked about managing 
conflicting evidence of studies when there is variability in the quality and/or sub-
populations of the published evidence. 
 
2.3. Reliability Testing 
 
The second part of this study; evaluating the framework reliability, followed the 
completion of the first part and used the validated and updated version of the GRASP 
framework. Two independent and experienced researchers were trained, for four hours 
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each by the authors, on using the framework to grade predictive tools. The researchers 
were then asked to grade eight different predictive tools independently, using the 
GRASP framework, the full text studies describing the development of the tools, and the 
comprehensive list of all the published evidence on each tool along with the full text of 
each study. The objective of this part of the study was to measure the reliability of 
using the framework, by independent users, to grade predictive tools. Since the tested 
function of the GRASP framework here is grading tools, the interrater reliability was the 
best measure to evaluate its reliability. The interrater reliability, also called interrater 
agreement, is the degree of agreement or the score of how much homogeneity, or 
consensus, there is in the ratings given by independent judges [30]. Since the target 
ratings of the GRASP framework are ordinal, the correlation testing is an appropriate 
method for showing the interrater reliability. The Spearman's rank correlation 
coefficient is the best nonparametric correlation estimator. It is widely used in the 
applied sciences and reported to be a robust measure of correlation [31]. After grading 
the tools, the two independent researchers were asked to provide their open-ended 
feedback. Through a short five questions survey, they were asked if the GRASP 
framework design was logical, if they found it useful, easy to use, their opinion in the 
criteria used for grading, and if they wish to add, remove, or change any of them. 
 
2.4. Analysis and Outcomes 
 
Three major outcomes were planned. Firstly, through the eight closed-ended 
agreement questions of the survey, the average scores and distributions of experts’ 
opinions on the different criteria used by the GRASP framework to grade and assess the 
predictive tools should help to improve such criteria. A five-points Likert scale ranging 
from strongly agree to strongly disagree was used, where the first was assigned the 
score of five and the last was assigned the score of one, to translate qualitative values 
into quantitative measures for the sake of the analysis [32, 33]. Secondly, the six open-
ended free text questions should provide experts with the opportunity to suggest 
adding, removing or updating any of the framework criteria. The qualitative analysis 
should help categorise such suggestions and recommendations into specific 
information and should also support updating the framework design and detailed 
content. The qualitative data analysis was conducted using the NVivo Version 12.3 
software package [34]. Thirdly, an interrater reliability testing was designed to measure 
how accurate and consistent the grading of eight predictive tools, conducted by two 
independent researchers, compared to each other and compared to the grading of the 
same tools by the authors. 
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3. Results 
 
The literature search generated a list of 1,186 relevant publications. A total of 
882 unique emails were identified and extracted from the publications. In six weeks; 
from the 4
th
 of October to the 15
th
 of November 2018, a total of eighty-one valid 
responses were received from international experts, with a response rate of 9.2%. 
 
3.1. Experts Agreement on GRASP Criteria 
 
The overall average agreement of the eighty-one respondents to the eight closed-
ended questions was 4.35; which means the respondents strongly agreed, overall, to the 
criteria of the GRASP framework. Respondents strongly agreed to six of the eight closed-
ended agreement questions, regarding the criteria used by the GRASP framework for 
evaluating predictive tools. They somewhat agreed to one, and were neutral about 
another one, of the eight closed-ended agreement questions. Table 1 shows the average 
agreements of the respondents on each of the eight closed-ended questions and Figure 
2 shows the averages and distributions of respondents’ agreements on each question. 
The country distributions of the respondents are shown in Table 6 in the Appendix. 
 
Table 1: Average Agreements of Expert Respondents on Framework Criteria 
SN Question Score Meaning 
1 
Predictive Performance: We should consider the evidence on validating the 
tool's predictive performance. 
4.87 Strongly Agree 
2 
Predictive Performance Level: The evidence level could be High (internal + 
multiple external validation), Medium (internal + external validation once), 
or Low (internal validation only). 
4.44 Strongly Agree 
3 Usability: We should consider the evidence on the tool's usability. 4.68 Strongly Agree 
4 
Potential Effect: We should consider the evidence on the tool's potential 
effect. 
4.61 Strongly Agree 
5 
Usability is Higher: The evidence level on tools' usability should be 
considered higher than the evidence level on tools' potential effect. 
2.97 
Neither Agree 
nor Disagree 
6 
Impact: We should consider the evidence on the tool's impact on healthcare 
effectiveness, efficiency or safety. 
4.78 Strongly Agree 
7 
Impact Level: The evidence level could be High (based on experimental 
studies), Medium (observational studies), or Low (subjective studies). 
4.16 
Somewhat 
Agree 
8 
Evidence Direction: Based on the conclusions of published studies, the 
overall evidence direction could be Positive, Negative or Mixed. 
4.26 Strongly Agree 
Overall Average 4.35 
Strongly 
Agree 
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Figure 2: Averages & distributions of respondents’ agreements: A - Predictive 
Performance, B - Performance Levels, C - Usability, D - Potential Effect, E - Usability is 
Higher than Potential Effect, F - Impact, G - Impact Levels, and H - Evidence Direction 
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3.2. Experts Comments, Suggestions and Recommendations 
 
While the total valid responses were eighty-one; two thirds of the respondents, 
on average, provided their suggestions or discussed some recommendations for each of 
the six open-ended free text questions. These questions asked experts for their feedback 
regarding adding, removing or changing any of the GRASP framework evaluation 
criteria, their feedback regarding defining and capturing successful tools’ predictive 
performance, when different clinical predictive tasks have different predictive 
requirements, and their feedback regarding managing conflicting evidence of studies 
while there is variability in the quality and specifications of published evidence. 
 
3.2.1. Predictive Performance and Performance Levels 
 
The respondents discussed that the method, type, and quality of internal and 
external validation studies should be reported in the GRASP framework detailed report. 
When external validation studies are conducted multiple times using different patient 
populations, in different healthcare settings, at different institutions, in different 
countries, over different times, or by different researchers then the tool is said to have 
a broad validation range, which means it is more reliable to be used across these 
different variations of healthcare settings. The respondents said that the tool’s 
predictive performance is considered stable and reliable, when multiple external 
validation studies produce homogeneous predictive performances, e.g. similar 
sensitivities and specificities. They also discussed adding the concept of “Strength of 
Evidence”; which should be mainly based on the quality of the reported study and how 
much the conditions of the study are close to the original specifications of the 
predictive tool, in terms of clinical area, population, and target outcomes. It should be 
part of the components of deciding the direction of evidence (positive, negative, or 
mixed). It should also be reported in the detailed GRASP framework report, so that users 
can consider when selecting among two or more tools of the same assigned grade. For 
example, two predictive tools are assigned grade C1 (each was externally validated 
multiple times) but one of them shows a strong positive evidence and the other shows a 
medium or weak positive evidence. It is logic to select the tool with the stronger 
evidence, if both have similar predictive performances for the same tasks. 
 
3.2.2. Usability and Potential Effect 
 
The respondents discussed that the methods and quality of the usability studies 
and the potential effect studies should be reported in the GRASP framework detailed 
report. Some of the respondents discussed that the potential effect and usability are not 
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measured during implementation, rather they are measured during the planning for 
implementation, which is before wide-scale implementation. They also suggested that 
the details on the potential effect should report the focus on clinical patient outcomes, 
healthcare outcomes, or provider behaviour. Most of the respondents said that the 
potential effect is more important than the usability and should have a higher evidence 
level. A highly usable tool that has no potential effect on healthcare is useless, while a 
less usable tool that has a promising potential effect is surely better. Some respondents 
discussed that evaluating both the potential effect and the usability should be 
considered together as a higher evidence than any of them alone.  
 
3.2.3. Post-Implementation Impact and Impact Levels 
 
The respondents discussed that the method and quality of the post-
implementation impact study should be reported in the GRASP framework detailed 
report. Again, respondents discussed adding the concept of “Strength of Evidence”. 
Within each evidence level of the post-implementation impact we could have several 
sub-levels, or at least a classification of the quality of studies. for example, not all 
observational studies are equal in quality; a case series would be very different to a case 
control or large-scale prospective cohort study. Within the experimental studies we 
could also have different sub-levels of evidence, quasi-experimental vs. randomised 
controlled trial for example. These sub-levels should be included in the GRASP 
framework detailed report, when reporting the individual studies, this will provide the 
reader with more details on the strength and quality of the evidence on the tools.  
 
3.2.4. Direction of Evidence 
 
Respondents discussed that the direction of evidence should consider the quality 
and strength of evidence. Most respondents here used the terms; “quality of evidence” 
and “strength of evidence”, synonymously. Respondents discussed that quality of 
evidence or the strength of evidence should consider many elements of the published 
study, such as the methods used, the appropriate population, appropriate settings, the 
clinical practice, the sample size, the type of data collection; retrospective vs 
prospective, the outcomes, the institute of study and any other quality measures. The 
direction of evidence depends largely on the quality of the evidence, in case there are 
conflicting conclusions from multiple studies. 
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3.2.5. Defining and Capturing Predictive Performance 
 
Respondents discussed that the predictive performance evaluation depends 
basically on the intended prediction task, so this is different from one tool to another, 
based on the task that each tool does. The clinical condition under prediction and the 
cost-effectiveness of treatment would highly influence the predictive performance 
evaluation. Predictive performance evaluation depends also on the actions 
recommended based on the tool. For example, screening tools should perform with high 
sensitivity, high negative predictive value, and low likelihood ratio, since there is a 
following level of checking by clinicians or other tests, while diagnostic tools should 
always perform with high specificity, high positive predictive value, and high likelihood 
ratio, since the decisions are based here directly on the outcomes of the tool, and some 
of these decisions might be risky to the patient or expensive to the healthcare 
organisation. Respondents discussed that for diagnostic tools, predictive performance 
is more likely to be expressed through sensitivity and specificity, while for prognostic 
tools, it is better to express predictive performance through probability/risk estimation. 
Predictive tools must always be adjusted to the settings, populations, and the intended 
tasks before their adoption and implementation in the clinical practice. 
 
3.2.6. Managing Conflicting Evidence 
 
Respondents discussed that deciding on the conflicting evidence should consider 
the quality of each study or the strength of evidence, to decide on the overall direction 
of evidence. Measures include the proper methods used in the study, if the population 
is appropriate, if the settings are appropriate, if the study is conducted at the clinical 
practice, if the sample size is large, if the data collection was prospective not 
retrospective, if the outcomes are clearly reported, if the institute of the study is 
credible, if the study involved multiple sites or hospitals, and any other quality 
measures related to the methods or the data. We should rely primarily on conclusions 
from high-quality low risk of bias studies, as recommended in other fields, e.g. 
systematic reviews. A well designed and conducted study should have more credibility 
than a poorly designed and conducted study. If different results are obtained for sub-
populations, this should be further investigated and explained. The predictive tool may 
only perform well in certain sub-populations, based on the intended tasks. If we have 
evidence from settings outside the target population of the tool, then these shouldn't 
have much weight, or less weight, on the evidence to support the tool, such as non-
equivalent studies; which are conducted to validate a tool for a different population, 
predictive task, or clinical settings. Much of the important information is in the details 
of the evidence variability. So, it is important to report this in the framework detailed 
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report, to provide as much details as possible for each reported study to help end users 
make more accurate decisions based on their own settings, intended tasks, target 
populations, practice priorities, and improvement objectives. 
 
3.3. Updating the GRASP Framework 
 
Based on the respondents’ feedback, on both the closed-ended evaluation criteria 
agreement questions and the open-ended suggestions and recommendations questions, 
the GRASP framework concept was updated, as shown in Figure 3. Regarding Phase C; 
the pre-implementation phase including the evidence on predictive performance 
evaluation, the three levels of internal validation, external validation once, and external 
validation multiple times, were additionally assigned “Low Evidence”, “Medium 
Evidence”, and “High Evidence” labels respectively. Phase B; During Implementation, has 
been renamed to “Planning for Implementation”. The Potential Effect is now made of 
higher evidence level than Usability and the evidence of both potential effect and 
usability together is higher than any one of them alone. Now we have three levels of 
evidence; B1 = both potential effect and usability are reported, B2 = Potential effect 
evaluation is reported, and B3 = Usability testing is reported. Figure 4 in the Appendix 
shows a clean copy of the updated GRASP framework concept. 
 
The GRASP framework detailed report was also updated, as shown in Table 4 in 
the Appendix. More details were added to the predictive tools information section, such 
as the internal validation method, dedicated support of research networks, programs, or 
professional groups, the total citations of the tool, number of studies discussing the 
tool, the number of authors, sample size used to develop the tool, the name of the 
journal which published the tool and its impact factor. Table 5 in the Appendix shows 
the Evidence Summary. This summary table provides users with more information in a 
structured format on each study discussing the tools, whether these were studies of 
predictive performance, usability, potential effect or post-implementation impact. 
Information includes study name, country, year of development, and phase of 
evaluation. The evidence summary provides more quality related information, such as 
the study methods, the population and sample size, settings, practice, data collection 
method, and study outcomes. Furthermore, the evidence summary provides information 
on the strength of evidence and a label, to highlight the most prominent or important 
predictive functions, potential effects or post-implementation impacts of the tools. 
 
We developed a new protocol to decide on the strength of evidence. The strength 
of evidence protocol considers two main criteria of the published studies. Firstly, it 
considers the degree of matching between the evaluation study conditions and the 
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original tool specifications, in terms of the predictive task, target outcomes, intended 
use and users, clinical specialty, healthcare settings, target population, and age group. 
Secondly, it considers the quality of the study, in terms of the sample size, data 
collection, study methods, and credibility of institute and authors. Based on these two 
criteria, the strength of evidence is classified into 1) strong evidence: matching 
evidence of high quality, 2) medium evidence: matching evidence of low quality or non-
matching evidence of high quality, and 3) weak evidence: non-matching evidence of low 
quality. Figure 7 in the Appendix shows the strength of evidence protocol. 
 
 
Figure 3: The Updated GRASP Framework Concept 
 
3.4. The GRASP Framework Reliability 
 
The two independent researchers assigned grades to the eight predictive tools 
and produced a detailed report on each one of them. The summary of the two 
independent researchers assigned grades, compared to the authors, are shown in Table 
2. A more detailed information on the justification of the assigned grades is shown in 
the Appendix in Table 7. The Spearman's rank correlation coefficient was 0.994 
(p<0.001) comparing the first researcher to the authors, 0.994 (p<0.001) comparing the 
second researcher to the authors, and 0.988 (p<0.001) comparing the two researchers to 
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each other. This shows a statistically significant and strong correlation, indicating a 
strong interrater reliability of the GRASP framework. Accordingly, the GRASP framework 
produced reliable and consistent grades when it was used by independent users. Both 
independent researchers found GRASP framework design logical, easy to understand, 
and well organized. They both found GRASP useful, considering the variability of tools’ 
quality and levels of evidence. They both found it easy to use. They both thought the 
criteria used for grading were logical, clear, and well structured. They did not wish to 
add, remove, or change any of the criteria. However, they asked for adding some 
definitions and clarifications to the criteria, which was included in the update. 
 
Table 2: Grades Assigned by the Two Independent Researchers and the Authors 
Tools 
Grading by 
Researcher 1 
Grading by 
Researcher 2 
Grading by 
Authors 
Centor Score [35] B2 B3 B3 
CHALICE Rule [36] B2 B2 B2 
Dietrich Rule [37] C0 C0 C0 
LACE Index [38] C1 C1 C1 
Manuck Scoring System [39] C2 C2 C2 
Ottawa Knee Rule [40] A1 A2 A1 
PECARN Rule [41] A2 A2 A2 
Taylor Mortality Model [42] C3 C3 C3 
 
4. Discussion and Conclusion 
 
4.1. Brief Summary 
 
It is a challenging task for most clinicians to critically evaluate a growing number 
of predictive tools, proposed in the literature, in order to select effective tools for 
implementation at their clinical practice or for recommendation in clinical practice 
guidelines, to be used by other clinicians. Although most of these predictive tools have 
been assessed for predictive performance, only a few have been implemented and 
evaluated for comparative effectiveness or post-implementation impact. Clinicians need 
an evidence-based approach to provide them with standardised objective information 
on predictive tools to support their search for and selection of effective tools for their 
clinical tasks. Based on the critical appraisal of the published evidence on predictive 
tools, the GRASP framework uses three dimensions to grade predictive tools: 1) Phase of 
Evaluation, 2) Level of Evidence and 3) Direction of Evidence. The final grade assigned 
to a tool is based on the highest phase of evaluation, supported by the highest level of 
positive evidence, or mixed evidence that supports a positive conclusion. In this paper, 
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we present the validation of the GRASP framework through the feedback of a wide 
international group of experts, where the GRASP framework concept, evaluation criteria, 
and the detailed report have been updated based on their feedback. The reliability 
testing showed that the GRASP framework can be used reliably and consistently by 
independent users to grade predictive tools. 
 
4.2. Predictive Performance 
 
The internal validation of the predictive performance of a tool is essential to 
make sure the tool is doing the prediction task as designed [43, 44]. The predictive 
performance is evaluated using measures of discrimination and calibration [45]. While 
discrimination refers to the ability of the tool to distinguish between patients with and 
without the outcome under consideration, calibration refers to the accuracy of the 
prediction, and show how much the predicted and the observed outcomes agree [46]. 
Discrimination is usually measured through sensitivity, specificity, and the area under 
the curve (AUC) [47]. On the other hand, calibration could be summarised using the 
Hosmer-Lemeshow test or the Brier score [48]. The external validation of predictive 
tools is essential to reflect the reliability and generalisability of the tools [49]. Predictive 
tools are more reliable and trustworthy, not only when their predictive performance is 
better, but more importantly when they undergo high quality, multiple, and wide range 
external validation [50]. The high quality is usually reflected in the type and size of data 
samples used in the validation, while repeating the external validations on different 
patient populations, at different institutions, in different healthcare settings, and by 
different researchers shows higher reliability of the predictive tools [44]. 
 
4.3. Usability and Potential Effect 
 
In addition to the predictive performance, clinicians are usually interested to 
learn about the potential effects of the tools on improving patient outcomes, saving 
time, costs and resources, or supporting patient safety [2, 51]. They need to know more 
about the expected impact of using the tool on different healthcare aspects, processes 
or outcomes, assuming the tool has been successfully implemented in the clinical 
practice [52, 53]. If a CDS tool has less potential to improve healthcare processes or 
clinical outcomes it will not be easily adopted or successfully implemented in the 
clinical practice [54]. Some clinicians might also be interested to learn about the 
usability of predictive tools; whether these tools can be used by the specified users to 
achieve specified and quantifiable objectives in the specified context of use [55, 56]. 
CDS tools with poor usability will eventually fail, even if they provide the best 
performance or potential effect on healthcare [7, 57]. Usability includes several 
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measurable criteria, based on the perspectives of the stakeholders, such the mental 
effort needed, the user attitude, interaction, easiness of use, and acceptability of 
systems [58, 59]. Usability can also be evaluated through measuring the effectiveness of 
task management with accuracy and completeness, the efficiency of utilising resources, 
and the users’ satisfaction, comfort with, and positive attitudes towards, the use of the 
tools [60, 61], in addition to learnability, memorability and freedom of errors [62, 63]. 
 
4.4. Post-Implementation Impact 
 
Clinicians are interested to learn about the post-implementation impact of CDS 
tools, on different healthcare aspects, processes, and outcomes, before they consider 
their implementation in the clinical practice [64-66]. The most interesting part of the 
impact studies for clinicians is the effect size of the CDS tools and their direct impact 
on physicians’ performance and patients’ outcomes [67, 68]. Clinicians consider that 
high quality experimental studies, such as randomised controlled trials, are the highest 
level of evidence, followed by observational well-designed cohort or case-control 
studies and lastly subjective studies, opinions of respected authorities, and reports of 
expert committees or panels [69-71]. For many years, experimental methods have been 
viewed as the gold standard for evaluation, while observational methods were 
considered to have little or no value. However, this ignores the limitations of 
randomised controlled trials, which may prove unnecessary, inappropriate, inadequate, 
or sometimes impossible. Furthermore, high-quality observational studies have an 
important role in comparative effectiveness research because they can address issues 
that are otherwise difficult or impossible to study. Therefore, we need to understand 
the complementary roles of the two approaches and appreciate the scientific rigour in 
evaluation, regardless of the method used [72, 73].  
 
4.5. Direction of Evidence and Conflicting Conclusions 
 
It is not uncommon to encounter conflicting conclusions when a predictive tool 
is validated or implemented and evaluated in different patient subpopulations or for 
different prediction tasks or outcomes [74, 75]. The cut-off value that determines what a 
good predictive performance is, for example, depends not only on the clinical condition 
under consideration but largely on the requirements, conditions, and consequences of 
the decisions made accordingly [76]. One of the main challenges here is dealing with the 
huge variability in the quality, types, and conditions of studies published in the 
literature. This variability makes it impossible to synthesise different measures of 
predictive performance, usability, potential effect or post-implementation impact into 
simple quantitative values, like in meta-analysis or systematic reviews [77, 78]. 
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4.6. The GRASP Framework Overall 
 
The grades assigned to predictive tools, using the GRASP framework, provide 
relevant evidence-based information to guide the selection of predictive tools for 
clinical decision support. However, the framework is not meant to be precisely 
prescriptive. An A1 tool is not always and absolutely better than an A2 tool. A clinician 
may prefer an A2 tool showing improved patient safety in two observational studies 
rather than an A1 tool showing reduced healthcare costs in three experimental studies. 
It all depends on the objectives and priorities the users are trying to achieve, through 
implementing and using predictive tools in their clinical practice. More than one 
predictive tool could be endorsed, in clinical practice guidelines, each supported by its 
requirements and conditions of use and recommended for its most prominent outcome 
of predictive performance, potential effect, or post-implementation impact on 
healthcare and clinical outcomes. The GRASP framework remains a high-level approach 
to provide clinicians with an evidence-based and comprehensive, yet simple and 
feasible, method to evaluate and select predictive tools. However, when clinicians need 
further information, the framework detailed report provides them with the required 
details to support their decision making. 
 
4.7. Challenges, Limitations, and Future Work 
 
It might be easy to analyse the feedback of experts using closed-ended 
questions. However, analysing the feedback of experts using open-ended questions is 
rather difficult [79]. Qualitative content and thematic analysis of free text feedback is 
challenging, since the extraction of significance becomes more difficult with diverse 
opinions, different experiences, and variable perspectives [80]. It is advised by many 
healthcare researchers to use Delphi techniques to reach to consensus among experts, 
through successive rounds of feedback, when developing clinical guidelines or selecting 
evaluation criteria and indicators [81-83]. However, using the Delphi techniques was not 
feasible in our study. 
 
Even though we contacted a large number of 882 experts, in the area of 
developing, implementing and evaluating predictive tools and CDS systems, we got a 
very low response rate of 9.2%, and received only 81 valid responses. This low response 
rate could have been improved if participants were motivated by some incentives, more 
than just acknowledging their participation in the study, or if more support was 
provided through the organisations these participants belong to, which needs much 
more resources to synchronise these efforts. For the sake of keeping the survey feasible 
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for most busy experts, the number of the closed ended as well as the open-ended 
questions were kept limited and the required time to complete the whole survey was 
kept in the range of 20 minutes. However, some of the participants could have been 
willing to provide more detailed feedback, through interviews for example, which was 
out of the scope of this study and was not initially possible to conduct with all the 
invited experts, otherwise we would have received a much lower response rate. 
 
To evaluate the impact of the GRASP framework on clinicians’ decisions and 
examine the application of the framework to grade predictive tools, the authors are 
currently working on two more studies. The first study should validate and evaluate the 
impact of using the framework on improving the decisions made by end user clinicians 
and healthcare professionals, regarding selecting predictive tools for the clinical tasks. 
Through an online survey of a wide international group of clinicians and healthcare 
professionals, the study should compare the performance and outcomes of making 
decisions with and without using the framework. The second study aims to apply the 
framework to a large consistent group of predictive tools, used for the same clinical 
prediction task. This study should show how the framework provides clinicians with an 
evidence-based method to compare, evaluate, and select predictive tools, through 
grading and reporting tools based on the critical appraisal of their published evidence. 
 
To enable end user clinicians and clinical practice guideline developers to access 
detailed information, reported evidence and assigned grades of predictive tools, it is 
essential to discuss implementing the GRASP framework into an online platform. 
However, maintaining such grading system up to date is a challenging task, as this 
requires the continuous updating of the predictive tools grading and assessments, when 
new evidence becomes published and available. It is important to discuss using 
automated or semi-automated methods for searching and processing new information 
to keep the GRASP framework updated. Finally, we recommend that the GRASP 
framework be utilised by working groups of professional organisations to grade 
predictive tools, in order to provide consistent results and increase reliability and 
credibility for end users. These professional organisations should also support 
disseminating such evidence-based information on predictive tools, in a similar way of 
announcing and disseminating new updates of clinical practice guidelines. 
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7. The Appendix 
 
7.1. The GRASP Framework Detailed Report 
 
Table 3: The GRASP Framework Detailed Report 
Name Name of predictive tool (report tool’s creators and year in the absence of a given name) 
Authors/Year Name of developer, country and year of publication 
Intended use Predictive task/specific aim/intended use of the predictive tool 
Intended user Type of practitioner intended to use the tool (e.g. physician or nurse) 
Category Diagnostic/Therapeutic/Prognostic/Preventive 
Clinical area Clinical specialty 
Target Population Target patient population and health care settings in which the tool is applied 
Target Outcome Event to be predicted (including prediction lead time if needed) 
Action Recommended action based on tool’s output 
Input source 
• Clinical (including Diagnostic, Genetic, Vital signs, Pathology) 
• Non-Clinical (including Healthcare Utilisation) 
Input type 
• Objective (Measured input; from electronic systems or clinical examination) 
• Subjective (Patient reported; history, checklist …etc.) 
Local context Is the tool developed using location-specific data? (e.g. life expectancy tables) 
Methodology Type of algorithm (e.g. parametric/non-parametric) 
Endorsement Organisations endorsing the tool and/or guidelines recommending its utilisation 
Automation Flag Automation status (manual/automated) 
Phase of 
Evaluation 
Level of Evidence Grade Evaluation Studies 
Phase C: 
 
Before 
implementation 
 
Is it possible? 
Insufficient 
internal validation 
C0 
Tested for internally validity but was either insufficiently 
internally validated or validation was insufficiently reported. 
Internal validation C3 
Tested for internally validity (reported calibration & 
discrimination; sensitivity, specificity, positive and negative 
predictive values & other performance measures). 
External validation C2 Tested for external validity, using one external dataset. 
External validation 
multiple times 
C1 
Tested multiple times for external validity, using more than one 
external dataset. 
Phase B:  
 
During 
implementation  
 
Is it practicable? 
Potential effect B2 
Reported estimated potential effect on clinical effectiveness, 
patient safety or healthcare efficiency. 
Usability B1 
Reported usability testing (effectiveness, efficiency, satisfaction, 
learnability, memorability, and minimizing errors). 
Phase A: 
 
After 
implementation: 
  
Is it desirable? 
Evaluation of post 
implementation 
impact on Clinical 
Effectiveness, 
Patient Safety or 
Healthcare 
Efficiency 
A3 
Based on subjective studies; e.g. the opinion of a respected 
authority, clinical experience, a descriptive study, or a report of 
an expert committee or panel. 
A2 
Based on observational studies; e.g. a well-designed cohort or 
case-control study. 
A1 
Based on experimental studies; properly designed, widely 
applied randomised/nonrandomised controlled trial. 
Final Grade Grade ABC,123 A1 A2 A3 B1 B2 C1 C2 C3 
Direction of 
Evidence 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
Justification 
Explains how the final grade is assigned based on evidence; which conclusions were taken into 
consideration, as positive evidence, and which were considered negative. 
References 
Details of studies supporting justification: phase of evaluation, level of 
evidence, direction of evidence, study type, study settings, methodology, 
results, findings and conclusions (highlighted according to colour code). 
These two sections 
are included in the 
full GRASP report on 
each tool. Label/Colour Code 
• Positive Findings  
• Negative Findings 
• Important Findings  
• Less Relevant Findings 
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7.2. The Updated GRASP Framework Concept 
 
 
Figure 4: The Updated GRASP Framework Concept 
 
7.3. The Updated GRASP Framework Detailed Report 
 
Table 4: The Updated GRASP Framework Detailed Report 
Name Name of predictive tool (report tool’s creators and year in the absence of a given name) 
Author Name of developer (first author or researcher) 
Country Country of development 
Year Year of development 
Category Diagnostic/Therapeutic/Prognostic/Preventive 
Intended use Predictive task/specific aim/intended use of the predictive tool 
Intended user Type of practitioner intended to use the tool (e.g. physician or nurse) 
Clinical area Clinical specialty 
Target Population Target patient population and health care settings in which the tool is applied 
Target Outcome Event to be predicted (including prediction lead time if needed) 
Action Recommended action based on tool’s output 
Input source 
• Clinical (including Diagnostic, Genetic, Vital signs, Pathology) 
• Non-Clinical (including Healthcare Utilisation) 
Input type 
• Objective (Measured input; from electronic systems or clinical examination) 
• Subjective (Patient reported; history, checklist …etc.) 
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Local context Is the tool developed using location-specific data? (e.g. life expectancy tables) 
Methodology Type of algorithm used for developing the tool (e.g. parametric/non-parametric) 
Internal Validation Method of internal validation 
Dedicated Support Name of the supporting/funding research networks, programs, or professional groups 
Endorsement Organisations endorsing the tool and/or clinical guidelines recommending its utilisation 
Automation Flag Automation status (manual/automated) 
Tool Citations Total citations of the tool 
Studies Number of studies reporting the tool 
Authors No Number of authors  
Sample Size Size of patient/record sample used in the development of the tool 
Journal Name Name of the journal that published the tool’s primary development study 
Journal Rank Impact factor of the journal 
Citation Index Calculated as: Average Annual Citations = number of citations/age of primary publication 
Publication Index Calculated as: Average Annual Studies = number of studies/age of primary publication 
Literature Index Calculated as: Citations and Publications = number of citations X number of studies 
Phase of 
Evaluation 
Level of Evidence Grade Evaluation Studies 
Phase C: 
 
Before 
implementation 
 
Is it possible? 
Insufficient 
internal validation 
C0 
Not tested for internal validity, insufficiently internally 
validated, or internal validation was insufficiently reported. 
Internal validation C3 
Tested for internally validity (reported calibration & 
discrimination; sensitivity, specificity, positive and negative 
predictive values & other performance measures). 
External validation C2 Tested for external validity, using one external dataset. 
External validation 
multiple times 
C1 
Tested multiple times for external validity, using more than one 
external dataset. 
Phase B:  
 
Planning for 
implementation  
 
Is it practicable? 
Usability B3 
Reported usability testing (tool effectiveness, efficiency, 
satisfaction, learnability, memorability, and minimizing errors). 
Potential effect B2 
Reported estimated potential effect on clinical effectiveness, 
patient safety or healthcare efficiency. 
Potential effect & 
Usability 
B1 Both potential effect and usability are reported. 
Phase A: 
 
After 
implementation: 
  
Is it desirable? 
Evaluation of post 
implementation 
impact on Clinical 
Effectiveness, 
Patient Safety or 
Healthcare 
Efficiency 
A3 
Based on subjective studies; e.g. the opinion of a respected 
authority, clinical experience, a descriptive study, or a report of 
an expert committee or panel. 
A2 
Based on observational studies; e.g. a well-designed cohort or 
case-control study. 
A1 
Based on experimental studies; properly designed, widely 
applied randomised/nonrandomised controlled trial. 
Final Grade Grade ABC/123 A1 A2 A3 B1 B2 B3 C1 C2 C3 
Tool Label 
One-word description of the most prominent prediction, potential effect or impact on healthcare 
processes or outcomes. E.g. “Grade A2 – Efficiency” (the tool improves efficiency by saving 
money, resources or time, proved through observational post-implementation impact studies). 
Direction of 
Evidence 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
Justification 
Explains how the final grade is assigned based on evidence; which conclusions were taken into 
consideration, as positive evidence, and which were considered negative. 
Evidence Summary 
Details of studies; using the Evidence Summary, to support the justification, where comparative 
predictive performance and effectiveness studies are highlighted. 
Findings Codes Positive Findings / Negative Findings / Important Findings 
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7.4. The Evidence Summary 
 
Table 5: The Evidence Summary 
Study The published study (According to Reference Style) 
Country Country of study 
Year Year of study 
Phase Before Implementation, planning for implementation, after Implementation 
Type 
Development / Internal Validation / External Validation / Usability / Potential Effect / Post-
Implementation Impact. 
Tools Single Tool vs Comparative Study (comparing multiple tools or one tool vs clinical practice). 
Intended use
 1
 Predictive task/specific aim/intended use of the predictive tool 
Intended user
 1
 Type of practitioner intended to use the tool (e.g. physician or nurse) 
Clinical Area
 1
 Clinical specialty 
Target Population
 1
 
Patients (age group, gender group, clinical specifications, e.g. cardiac population). Providers 
(age group, gender, clinical specifications, e.g. specialty). 
Settings 
1
 Inpatient, outpatient, intensive care … etc. 
Methods
 2
 
Tool development methods: recursive partitioning, multivariate logistic regression … etc. 
Internal validation methods: out-of-sample, bootstrapping, cross validation, split sample … 
etc. External validation methods: national, international … etc. Usability: acceptance, 
satisfaction, adoption … etc. Potential Effect: feasibility, cost-effectiveness, economic 
analysis … etc. Impact: experimental (randomised, non-randomised, controlled, quasi-
experimental), observational (cohort studies, case-control, cross-sectional), subjective (expert 
opinion, reports) … etc. 
Practice
 2
 Clinical vs non-clinical practice. 
Sample Size
 2
 Number of patients/records/users recruited in the study 
Data Collection
 2
 Prospective/retrospective data 
Outcomes
 2
 
Reported outcome measures: Development/Validation: reported calibration/discrimination; 
sensitivity, specificity, positive & negative predictive values & other performance measures. 
Usability: acceptance, satisfaction … etc. Potential Effect: feasibility, cost-effectiveness, 
economic analysis … etc. Impact: effect size, duration of implementation … etc. 
Institute
 2
 Name and type of hospital (Multiple hospitals, single hospital, tertiary care … etc). 
Support
 2
 Dedicated support of research networks, programs or groups. 
Authors
 2
 Number of researchers. 
Journal
 2
 Journal name and impact factor. 
Direction of Evidence  Positive / Equivocal / Negative (Based on study findings and conclusions). 
Matching of Evidence  Considering fields 
1
 (Matching/Non-Matching to the tool’s original specifications) 
Quality of Evidence  Considering fields 
2
 (High Quality/Low Quality of the study) 
Strength of Evidence 
Based on Evidence Matching and Quality: Strong Evidence / Medium Evidence / Weak 
Evidence 
Label Effectiveness / Efficiency / Safety / Workflow / Processes (one or more). 
Notes Special important study information. 
 
 
 
  
   33 
7.5. Experts’ Country Distributions 
 
Table 6: Country Distributions of Expert Respondents 
Country Responses Percent Cumulative 
United States 20 24.7% 24.7% 
United Kingdom 12 14.8% 39.5% 
Canada 8 9.9% 49.4% 
Netherlands 5 6.2% 55.6% 
Spain 5 6.2% 61.7% 
Australia & New Zealand 5 4.9% 67.9% 
Argentina 2 2.5% 70.4% 
Belgium 2 2.5% 72.8% 
Germany 2 2.5% 75.3% 
Europe 8 9.9% 85.2% 
Asia 6 7.4% 92.6% 
Africa 2 2.5% 95.1% 
South America 2 2.5% 97.5% 
Middle East 2 2.5% 100.0% 
Total 81 100% 
 
 
 
Figure 5: Country Distributions of Expert Respondents 
 
 
 
United States, 
25%
United 
Kingdom, 15%
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7.6. The Mixed Evidence Protocol 
 
Based on Evidence Matching, 
Quality of Studies, and 
Reported Conclusions
Predictive Performance, 
Potential Effect, Usability, or 
Post-Implementation Impact
Sample Size, Data Collection, 
Study Methods, Credibility of 
Institute/Authors
Predictive Task, Intended Use 
& Users, Clinical Specialty, 
Healthcare Settings, Target 
Population, Age Group
Step 1
Class A
Step 2
Matching Not Matching
Class B Class C
Evidence Matching Tool 
Specifications?
Evidence Quality
Evidence Conclusion on 
Reported Criteria
Mixed Evidence from 
Multiple Studies
Matching 
Evidence of 
High Quality
Matching Evidence of Low 
Quality OR Non-Matching 
Evidence of High Quality
Non-Matching 
Evidence of 
Low Quality
Step 3
Mixed Evidence 
Supporting 
Positive Conclusion
Mixed Evidence 
Supporting 
Negative Conclusion
Positive Negative
Deciding the Overall 
Direction of Evidence
Step 4
 
Figure 6: The Mixed Evidence Protocol 
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The Mixed Evidence Protocol  
 
The mixed evidence protocol is based on four steps. Firstly, it considers the degree of 
matching between the evaluation study conditions and the original tool specifications, 
in terms of the predictive task, outcome, intended use and users, clinical specialty, 
healthcare settings, target population, and age group. Secondly, it considers the quality 
of the study, in terms of sample size, data collection, study methods, and credibility of 
institute or authors. Based on these two criteria, the studies in the mixed evidence on 
the tool are classified into 1) Class A: matching evidence of high quality, 2) Class B: 
matching evidence of low quality or non-matching evidence of high quality, and 3) Class 
C: non-matching evidence of low quality. Thirdly, it considers the evidence conclusion 
on the reported evaluation criteria; the predictive performance, potential effect, 
usability, and post-implementation impact. In the fourth step, studies evaluating 
predictive tools in closely matching conditions to the tool specifications and providing 
high quality evidence, Class A, are considered first; taking into account their 
conclusions on the evaluation criteria in deciding the overall direction of evidence. On 
the other hand, studies evaluating predictive tools in different conditions to the tool 
specifications and providing low quality evidence, Class C, are considered last. The 
conclusion of one study in Class A is considered a stronger evidence than the 
conflicting conclusions of any number of studies in Class B or C, and the overall 
direction of the evidence is decided towards the conclusion of the study of Class A. 
When multiple studies of the same class; for example, Class A, report conflicting 
conclusions, then we compare the number of studies reporting positive conclusions to 
those reporting negative conclusions and the overall direction of the evidence is 
decided towards the conclusion of the larger group. If the two groups are of the same 
size, then we check if there are more studies in other classes, if not then we examine 
the reported evaluation criteria and their values in the two groups of studies. 
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7.7. The Strength of Evidence Protocol 
 
 
Sample Size, Data 
Collection, Study 
Methods, Credibility of 
Institute/Authors
Predictive Task, 
Intended Use & Users, 
Clinical Specialty, 
Healthcare Settings, 
Target Population, Age 
Group
Step 1
Strong Evidence
Step 2
Matching Not Matching
Medium Evidence Weak Evidence
Does Evidence Match Tool 
Specifications?
Evidence Quality
Evidence Strength
Matching 
Evidence of High 
Quality
Matching Evidence of Low 
Quality OR Non-Matching 
Evidence of High Quality
Non-Matching 
Evidence of Low 
Quality
 
Figure 7: The Strength of Evidence Protocol 
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7.8. Interrater Reliability Detailed Results 
 
Table 7: Grading the Predictive Tools by the Independent Researcher vs the Authors 
Tool 
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Impact After 
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A1 A2 A3 B1 B2 B3 C1 C2 C3 
Centor Score [35] 
R1 B2 
   
 
     
R2 B3 
 
   
   
 
 
A B3 
 
    
  
  
CHALICE Rule [36] 
R1 B2          
R2 B2     
 
 
 
 
 
A B2     
 
 
 
  
Dietrich Rule [37] 
R1 C0         
 
R2 C0          
A C0         
 
LACE Index [38] 
R1 C1          
R2 C1       
 
 
 
A C1       
 
  
Manuck Scoring 
System [39] 
R1 C2          
R2 C2        
  
A C2        
  
Ottawa Knee Rule [40] 
R1 A1 
   
 
     
R2 A2  
 
    
 
 
 
A A1 
 
     
 
 
 
PECARN Rule [41] 
R1 A2    
      
R2 A2  
 
 
  
 
 
 
 
A A2  
 
  
 
 
 
  
Taylor Mortality Model 
[42] 
R1 C3          
R2 C3          
A C3          
Direction of Evidence 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
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7.9. The Survey Screenshots 
 
Section 1: The survey introduction 
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Section 2: Criteria of evaluating tools’ predictive performance before implementation 
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Section 3: Criteria of evaluating tools’ usability and estimated potential effect 
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Section 4: Criteria of evaluating tools’ impact post-implementation 
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Section 5: Criteria of evaluating direction of published evidence 
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Section 6: Defining successful predictive performance and managing conflicting 
evidence. 
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Section 7: providing contacts to request feedback and acknowledgment 
 
